Some of the main goals of treatments for essential thrombocythemia include reducing disease progression and blood clots while improving symptom burden, but more treatments may be on the horizon ...
Risk stratification replaces “Stage 4” terminology, prioritizing prevention of arterial/venous thrombosis and bleeding events over tumor burden concepts. Diagnostic confirmation typically integrates ...
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs) RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...
Bleeding in ET can range from minor mucocutaneous events to severe hemorrhages, with gastrointestinal bleeding being most common. The JAK2 V617F variant increases bleeding and thrombosis risk, ...
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles ...
New Positive Data Showed INCA033989 Achieved Rapid, Robust & Sustained Clinical & Molecular Responses and Was Well Tolerated ...
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles ...
BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep ...
LOUISVILLE, Ky.--(BUSINESS WIRE)--Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by GlaxoSmithKline for OJJAARA™ (momelotinib). OJJAARA is a ...
Hemorrhagic events post-diagnosis in patients with ET significantly increase mortality risk, more than thrombosis or disease progression. Intracranial hemorrhage is the most lethal bleeding ...
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs) “The standard of care in essential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results